TransMedics Group (NASDAQ:TMDX) PT Lowered to $125.00 at Oppenheimer

TransMedics Group (NASDAQ:TMDX) had its price objective decreased by analysts at Oppenheimer from $200.00 to $125.00 in a research report issued to clients and investors on Tuesday, Briefing.com reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price objective points to a potential downside of 0.98% from the company’s current price.

A number of other brokerages also recently issued reports on TMDX. Stephens increased their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Morgan Stanley increased their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Robert W. Baird started coverage on shares of TransMedics Group in a report on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 target price for the company. Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a report on Monday, October 7th. Finally, Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $145.90.

TransMedics Group Trading Up 0.9 %

Shares of TransMedics Group stock opened at $126.24 on Tuesday. The company has a market capitalization of $4.21 billion, a price-to-earnings ratio of 3,156.00 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $177.37. The firm’s 50-day moving average price is $147.58 and its two-hundred day moving average price is $140.19.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.03) earnings per share. On average, analysts forecast that TransMedics Group will post 1.22 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the sale, the director now directly owns 732 shares in the company, valued at $109,770.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the sale, the insider now owns 20,843 shares in the company, valued at $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,205 shares of company stock valued at $9,981,907 in the last quarter. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the business. New York State Teachers Retirement System bought a new stake in shares of TransMedics Group during the 3rd quarter worth $1,217,000. State of Alaska Department of Revenue bought a new stake in TransMedics Group in the 3rd quarter valued at about $2,560,000. Louisiana State Employees Retirement System bought a new stake in TransMedics Group in the 3rd quarter valued at about $2,528,000. Guidance Capital Inc. bought a new stake in TransMedics Group in the 3rd quarter valued at about $370,000. Finally, Precision Wealth Strategies LLC bought a new stake in TransMedics Group in the 3rd quarter valued at about $236,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.